ゲノム編集革命の地図
CRISPR アトラス
遺伝子医療の未来を形づくる技術・治療・疾患・科学者・企業・臨床試験・発見を探ってみましょう。
Start where you actually are
This site is written for very different readers at once. Each door below leads into the same database from a different angle — nothing is dumbed down, and nothing assumes a biology degree.
New to all of thisStart with what DNA is and build up. No background needed.
A patient or familyWhat is approved, what is only in trials, and how to tell the difference.
Following the industryWho is developing what, at which stage. Information, never advice.
Here for food and farmingGene-edited crops and livestock, and why the rules differ by country.
遺伝子編集を探索する
科学者が遺伝物質を変える7つの方法。各ページはわかりやすい説明から始まり、知りたい深さまで掘り下げられます。
CRISPR-Cas9A protein that can be programmed with a short RNA guide to find one specific sequence in a genome and cut it.
Base EditingChemically converts one DNA letter into another at a chosen position, without cutting both strands of the double helix.
Prime EditingWrites a new stretch of DNA sequence directly into a chosen site, using a guide that carries the replacement text with it.
CRISPR-Cas12A family of CRISPR nucleases that cut DNA leaving staggered ends, use a different sequence requirement from Cas9, and can be smaller.
CRISPR-Cas13Targets RNA rather than DNA, so it can silence a gene's message without touching the genome itself.
Cas14 and miniature Cas systemsUnusually small CRISPR nucleases — roughly a third the size of Cas9 — discovered in archaea and bacteriophages.
RNA EditingChanges letters in the RNA message rather than in the DNA, so the effect is real but temporary and the genome is untouched.
並べて比較する精度・切断・カーゴサイズ・デリバリー・成熟度・リスク
対象疾患
各疾患ページには、遺伝子編集が承認済みの治療法なのか、臨床試験中なのか、まだ研究段階にすぎないのかが、わかりやすく記載されています。
Sickle Cell DiseaseBlood disorders
Beta ThalassemiaBlood disorders
ATTR AmyloidosisMetabolic disease
Hereditary AngioedemaRare genetic disease
High Cholesterol and Familial HypercholesterolemiaCardiovascular disease
CancerCancer
Leukemia and LymphomaCancer
HIVInfectious disease
Duchenne Muscular DystrophyMuscular disease
Cystic FibrosisRare genetic disease
治療法
すべての記録に規制状況が記載された、名称付きの医薬品。
Atlas掲載の承認済み遺伝子編集医薬品: Casgevy (exagamglogene autotemcel) · Lyfgenia (lovotibeglogene autotemcel) · Zynteglo (betibeglogene autotemcel)
臨床試験
エビデンスが実際に生まれる場所。
注目の企業
誰が何を開発しているか、そして各プログラムがどこまで進んでいるか。
CRSP · Zug, Switzerland
CRISPR Therapeutics
Co-founded by Emmanuelle Charpentier, and the company behind the first approved CRISPR…
NTLA · Cambridge, Massachusetts
Intellia Therapeutics
Co-founded by Jennifer Doudna, and the company that first delivered CRISPR into a human…
BEAM · Cambridge, Massachusetts
Beam Therapeutics
Founded by David Liu and colleagues to commercialise base editing — precision changes to…
EDIT · Cambridge, Massachusetts
Editas Medicine
One of the first CRISPR companies, which discontinued its cell-therapy and eye programmes…
PRME · Cambridge, Massachusetts
Prime Medicine
Founded to commercialise prime editing, and the company behind the first published…
非公開 · Boston, Massachusetts
Verve Therapeutics
Built to turn heart disease into a one-time treatment, and acquired by Eli Lilly in 2025…
CRBU · Berkeley, California
Caribou Biosciences
Co-founded by Jennifer Doudna, using hybrid RNA-DNA guides intended to make editing…
SANA · Seattle, Washington
Sana Biotechnology
Engineering transplanted cells to be invisible to the immune system, so they can be given…
この分野を変えた科学者たち
それぞれの人が実際に何に貢献したか――この分野では功績の帰属が争われており、その箇所を明示しています。
Jennifer DoudnaStructural biochemist who, with Emmanuelle Charpentier, showed that Cas9 could be programmed with a single guide RNA to cut chosen DNA — and shared the 2020 Nobel Prize in Chemistry for it.
Emmanuelle CharpentierMicrobiologist who discovered tracrRNA, the missing component of the CRISPR-Cas9 system, and shared the 2020 Nobel Prize in Chemistry with Jennifer Doudna.
Feng ZhangBioengineer who led one of the first demonstrations of CRISPR genome editing in human cells and discovered several new CRISPR systems including Cas12a and Cas13.
David LiuChemical biologist whose laboratory invented base editing and prime editing — the two techniques that changed gene editing from cutting to writing.
George ChurchGeneticist whose laboratory independently demonstrated CRISPR editing in human cells in 2013, and a founder of an unusually large number of genomics companies.
Virginijus ŠikšnysLithuanian biochemist who independently showed that Cas9 could be programmed to cut DNA, publishing in 2012 — and whose contribution is often omitted from popular accounts.
遺伝子編集の最新ニュース
実名の出版社による本物の記事です。すべての見出しは元の記事にリンクしており、私たちが書き直したり転載したりすることはありません。
CRISPRとは
最初の一歩から始めましょう。生物学の知識は必要ありません。
Start here
What is DNA?
DNA is a long chemical chain that stores the instructions for building and running a living thing, written in…
Start here
What is a gene?
A gene is a stretch of DNA that carries the instructions for making one particular thing the cell needs —…
Start here
What is a chromosome?
A chromosome is one very long DNA molecule packaged with proteins; humans normally have 46, in 23 pairs.
Start here
What is a genome?
A genome is the complete set of genetic instructions in an organism — every chromosome, every gene, and…
Start here
What is RNA?
RNA is DNA's working copy — a temporary, single-stranded version the cell makes when it needs to use a gene.
Start here
What is a mutation?
A mutation is a change in DNA sequence. Most do nothing, some cause disease, and a few are beneficial.
数字で見る遺伝子編集
アトラスデータベースのリアルタイム件数です。この分野全体の規模の推計ではなく、当サイトが保有する記録数です。
カウントはページを読み込むたびに更新されます。「承認済み」とは、国の医薬品規制当局が少なくとも1つの製品を承認したことを意味し、その治療法が特定の方に利用可能または適切であることを示すものではありません。
